Malaria prophylaxis in travellers: the current position.
Malaria prevention is a main challenge for physicians, nurses, health officers and tour operators. The attack rate of malaria in travellers is 1-10/10,000 departures, and the case fatality rate of imported malaria is around 0.5/100. Travellers should be informed about the risk they are going to take, how to protect against mosquito bites, about the antimalarials they will have to take and what to do when a malaria breakthrough should occur. The 4-aminoquinolines (chloroquine, amodiaquine) remain the drug of choice for the prevention of Plasmodium vivax and of sensitive P. falciparum infections. The problem is to find an effective and safe drug combination for travellers to areas where P. falciparum is either resistant to chloroquine, to Fansidar (the combination of pyrimethamine plus sulfadoxine) or to both. These travellers will probably best be protected by an individually tailored drug combination, which includes amodiaquine or mefloquine as baseline drugs, and a supplementation with Fansidar, Maloprim (the combination of pyrimethamine with dapsone), paludrine or an antibiotic.
D000349:Africa; D000655:Amodiaquine / Q000627:therapeutic use; D000962:Antimalarials / Q000627:therapeutic use*; D001208:Asia; D002738:Chloroquine / Q000627:therapeutic use; D009033:Culicidae; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007223:Infant; D007299:Insect Bites and Stings / Q000517:prevention & control; D007843:Latin America; D008288:Malaria / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission; D010963:Plasmodium falciparum; D010966:Plasmodium vivax; D011247:Pregnancy; D011319:Primaquine / Q000627:therapeutic use; D002727:Proguanil / Q000627:therapeutic use; D012306:Risk; D014195:Travel
D000962:Antimalarials; D000655:Amodiaquine; D002738:Chloroquine; D011319:Primaquine; D002727:Proguanil